- China Pharma Holdings filed a Form 12b-25 to delay its Form 10-K for fiscal year ended Dec. 31, 2025.
- Annual report expected within 15 calendar days of March 31, 2026.
- Filing cited time constraints from compiling, disseminating, and reviewing required disclosures.
- Preliminary results flagged significant year-over-year changes, including revenue of 4.1 million versus 4.5 million.
- Net loss expected at about 3.19 million versus about 4.74 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Pharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-038495), on April 01, 2026, and is solely responsible for the information contained therein.